Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Transitional Cell × bicalutamide × Genitourinary × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 122 Neoplasms 4 Neoplasm Metastasis 4 Prostate Adenocarcinoma 2 Osteoporosis 2 Hirsutism 2 Thrombocytosis 1 Stage I Prostate Adenocarcinoma AJCC v7 1 Stage I Prostate Adenocarcinoma 1 Sexual Dysfunction, Physiological 1 Recurrence 1 Primary Myelofibrosis 1 Primary Dysautonomias 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Pancreatic Neoplasms 1 PSA Level Greater Than Two 1 Non-Muscle Invasive Bladder Neoplasms 1 Non Castrate Metastatic Prostate Cancer 1 Myeloproliferative Disorders 1 Myelodysplastic-Myeloproliferative Diseases 1 Myelodysplastic Syndromes 1 Multiple Myeloma 1 Lymphoma, Non-Hodgkin 1 Lower Urinary Tract Symptoms 1 Leukemia, Myelomonocytic, Chronic 1 Leukemia, Myeloid, Chronic-Phase 1 Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1 Leukemia, Myeloid, Acute 1 Leukemia, Myeloid, Accelerated Phase 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1

Interventions

pembrolizumab 76 Gemcitabine 48 Nivolumab 41 Cisplatin 35 atezolizumab 34 Carboplatin 27 avelumab 25 enfortumab vedotin 23 Docetaxel 22 Magnetic Resonance Spectroscopy 17 Paclitaxel 15 Ipilimumab 15 Mitomycin 14 Specimen Handling 12 durvalumab 10 toripalimab 9 sacituzumab govitecan 9 Pemetrexed 8 vinflunine 7 cabozantinib 7 Taxes 7 Injections 6 Cyclophosphamide 6 Bevacizumab 6 tislelizumab 5 pemigatinib 5 Standard of Care 5 Fluorodeoxyglucose F18 5 Biopsy 5 lenvatinib 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06018116 2024-02-15

CANUCK-01

CHU de Quebec-Universite Laval

Phase 2 Withdrawn

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡